A B S T R A C T
Background. Early stages of diabetic nephropathy (DN) are characterized by an influx of inflammatory cells. Interactions between infiltrating T cells and podocytes may play an important role in the ongoing inflammatory response and remodelling. The aim of this study was to explore the role of IL-17 and CD40 ligand (CD40L) in DN. Methods. The study design involved a case series. Kidney biopsy samples of 69 patients with type 2 diabetes were assessed for the presence of CD4
þ IL-17 þ T cells. The number of CD4 þ IL-17 þ T cells were counted and correlated with clinical and laboratory findings. Additionally, advanced glycation end-products (AGEs) were added to cultured podocytes to imitate diabetic conditions and thus to elucidate the role of CD4 þ IL-17 þ T cells in renal sclerosis. Results. CD80 expression was detected in early phases of DN but was absent during diffused glomerurosclerosis in DN kidney specimens. In DN samples, CD40 expression was not only observed in most of the infiltrating cells, but also increased in podocytes and tubular epithelial cells. CD40L is locally expressed on infiltrating cells. CD4
þ IL-17 þ T cells were found in DN, and the number of CD4
þ IL-17 þ T cells was positively correlated with the deterioration in glomerular filtration rate (GFR). IL-17A was the key cytokine produced by CD4
þ IL-17 þ T cells. IL-17A levels were elevated in DN renal tissue and were correlated with declining GFR. IL-17 and CD40L synergistically enhanced IL-6, monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted (RANTES), transforming growth factor beta 1 (TGFb1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) production in vitro. AGEs induced podocyte activation with increasing expression of IL-17A, CD40 and TGF-b1 in vitro. Blockade with an anti-IL-17 monoclonal antibody reduced the expression of CD40 and TGF-b1, but increased the viability of cultured podocytes.
Conclusions. IL-17 and CD40L synergistically mediate the inflammatory response and remodelling associated with tissue injury and glomerular sclerosis in DN.
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I N T R O D U C T I O N
According to a previous report [1] , 25-40% of patients with type 2 diabetes will develop diabetic nephropathy (DN) in their lifetime. In recent years, DN has been the leading cause of end-stage renal disease (ESRD) in many countries [2] . Current treatment for type 2 diabetes mellitus includes maintaining serum sugar and blood pressure levels within target ranges. Even when target ranges are achieved, however, DN progresses continuously. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have anti-inflammatory effects; however, they are only effective in treating the microscopic albuminuria of early DN. This suggests that there are unknown mechanisms involved in DN that render these medications less than fully effective. Upon reviewing the pathogenesis of DN, it was found that current mechanistic studies focus on hyperglycaemia-induced metabolic and haemodynamic changes. Metabolic changes lead to advanced glycation end-products (AGEs), increased protein kinase C activity and abnormal polyol metabolism, which in turn results in increased secretion of inflammatory molecules such as cytokines, growth factors and metalloproteinases. There are limited reports on the immunological elements of DN, and although there are two reports of lymphocytes infiltrating into the juxtaglomerular apparatus [3, 4] , the roles of these lymphocytes in DN remain unclear.
B7-1 (CD80), an immune-related protein found on antigenpresenting cells, acts as a co-stimulatory signal with activated T cells by binding to the receptor CD28. Induction of 
podocyte CD80 is associated with the development of proteinuria in mice with lipopolysaccharide (LPS)-induced proteinuria [5] and CD80 knockout mice are protected from LPSinduced albuminuria, suggesting a causal link between podocyte CD80 expression and proteinuria [5] . CD80 plays an important role in T cell activation: the interaction of CD80 on podocytes with CD28 on T cells provides an important second signal for T cell activation [6] . CD40-CD40L cross-talk has been shown to play a central role in enhancing the release of IL-6 from antigen-presenting cells, which in turn promotes the development of Th17 responses [7] . In vitro, the activation of renal tubular cell (TEC) with IL-17 increases the production of IL-6, IL-8 and monocyte chemoattractant protein-1 (MCP-1) [8] . Both IL-17 and CD40L synergistically stimulate renal epithelial cells, resulting in the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) signalling, which plays a role in the development of fibrosis [8] .
Several studies have demonstrated a critical role for IL-17 in fibrosis models [9] [10] [11] [12] [13] [14] . Transforming growth factor beta 1 (TGF-b) contributes to tissue inflammation and fibrosis, and the diabetic kidney milieu contains increased levels of IL-6 and TGF-b, which are the key cytokines in CD4
þ IL-17 þ T cell development [15, 16] . To date, however, no link between CD4
þ IL-17 þ T cell-and CD40L-driven inflammation and renal sclerosis in DN has been established.
We hypothesize that infiltrating CD4 þ IL-17 þ T cells synergistically secrete IL-17 with CD40 ligand, contributing to renal sclerosis in DN. The aim of this study was thus to explore the roles of IL-17 and CD40L in the synergistic stimulation of renal sclerosis in DN. In particular, the aims were to assess whether (i) CD80 and CD40 are upregulated in kidney specimens of DN, (ii) CD4
þ IL-17 þ T cells infiltrate in kidney tissue of DN, (iii) IL-17 and CD40L synergistically enhance podocyte activation and the expression of cytokines and NF-jB, (iv) AGE induces IL-17 production and CD40 expression in podocytes and, (v) knockdown or neutralization of IL-17 limits TGF-b1 and CD40 expression.
M A T E R I A L S A N D M E T H O D S
This study was approved by the Institutional Review Board of China Medical University Hospital (DMR99-IRB-303). Patients who had type 2 diabetes mellitus and had received kidney biopsies in our institute were included in this study after informed consent was obtained. A patient who was reluctant to provide the stored biopsy specimen was excluded from this study. The diagnoses of diabetes were based on clinical symptoms, laboratory data and histological findings. Histological analyses were performed by staining with haematoxylin and eosin, periodic acid-Schiff, periodic acid-methenamine, Masson trichrome stains, immunohistochemistry and immunofluorescence.
Study design and participants
From 2007 to 2010, 69 type 2 DN patients (CKD stage 1-5) with heavy proteinuria were recruited for the study ( Table 1) . The female/male ratio of the study participants was 46/23 and the patient ages [mean 6 standard deviation (range)] were 64.00 610.71 (38-88 years).
Double immunohistochemistry
Formalin-fixed and paraffin-embedded renal biopsy specimens were treated according to the previously described protocol. The following primary anti-mouse monoclonal antibodies (Abs) were used at a 1:50 dilution: anti-CD3 Ab (Leica Microsystems Inc., Buffalo Grove, IL, USA), anti-CD4 Ab (Leica Microsystems Inc., NCL-CD4-IF6) and anti-IL-17A Ab (Abcam #969565, Cambridge, UK). Secondary rabbit monoclonal anti-IL-17A Ab (Abcam; ab54501) was used at a 1:750 dilution. CD4
þ IL-17 þ cell counts were calculated as positive cells per high power field at 400Â magnification from 10 randomly chosen fields within the same section of specimen from an individual patient.
Enzyme-linked immunosorbent assay
IL-17A concentrations in tissue sample homogenates were measured using specific enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) as described in the manufacturer's instructions and were normalized to total protein concentration determined by a protein assay (Bio-Rad Laboratories, Hemel Hempstead, UK). Concentrations of IL-17A in organ-culture supernatants were assessed using specific ELISA kits (R&D Systems) and sCD28 (sCD80 soluble ligand) concentrations were measured using a platinum ELISA kit (eBioscience, San Diego, CA, USA).
AGE-bovine serum albumin preparation
AGE-bovine serum albumin (BSA) was prepared by incubating BSA (Sigma, St Louis, MO, USA) with 500 mmol/L of Data are presented as mean 6 standard deviation (range) or n (number); HDL, highdensity lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; AC sugar, fasting blood sugar.
T c e l l s c o n t r i b u t e t o r e n a l s c l e r o s i s
D-glucose under aerobic conditions for 10 weeks at 37 C in the presence of protease inhibitors and antibiotics as described previously [17] .
Human podocyte culture
Conditionally immortalized human podocytes carrying a temperature-sensitive T-antigen transgene under the control of an interferon-c-inducible promoter were generated from the ImmortoMouse (Charles River, Wilmington, MA, USA) and were maintained in culture as described [18, 19] . To induce differentiation, podocytes were grown on type I collagen (BD Biosciences, Bedford, MA, USA) under permissive conditions at 33 C with interferon-c (10 U/mL) (Roche, Mannheim, Germany) or under non-permissive conditions at 37 C without interferon-c for at least 10 days. Podocytes were treated with R-568 (Amgen, Thousand Oaks, CA, USA). Podocyte injury was induced by treatment with polyacrylonitrile (Sigma) dissolved in 0.9% cyclodextrin.
Cell treatment
Cultured podocytes were treated with AGEs (10 mg/L, 25 mg/L, 50 mg/L and 100 mg/L for 48 h). In addition, anti-RAGE antibody (10 lg/mL; Abcam) was used to block the binding of AGEs to RAGE.
Western blot assay
Cells were harvested and lysed and total protein concentrations were determined. Samples were resolved by SDS-PAGE and electroblotted onto polyvinylindene difluoride membrane. Membranes were then incubated with either anti-human IL-17A (1:500 dilution; R&D Systems), mouse anti-human IL-17RC (1:750 dilution; Abcam), IL-6, CD40, MCP-1, regulated on activation, normal T cell expressed and secreted (RANTES) (MyBioSource, SanDiego, CA, USA) or anti-TGF-b1 (R&D Systems) overnight at 4 C, followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG for 1 h at room temperature. The signals were captured using a chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK) [20] .
Cell viability and MTT assays
Podocytes were plated in microtiter plates at a density of 3 Â 10 5 cells/mL. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well (final concentration: 0.5 mg/mL) after which the plates were incubated for an additional 2 h at 37 C. The resulting absorbance levels were then quantified spectroscopically at 560 nm using a SpectrMaxV R 190 spectrophotometer [21] .
Immunofluorescence staining
The following human renal tissues were used: 10 healthy kidneys from a normal part of nephrectomy for angiomyolipoma with massive bleeding or scheduled biopsy from living related kidney donor and 10 percutaneous biopsies of DN. Formalinfixed tissue sections were kept in water-free acetone at room temperature for 10 min. After washing and blocking with 0.03% H 2 O 2 , sections were incubated with 20 lg/mL anti-CD80 mAb (GeneTex, Irvine, CA, USA), anti-CD40 mAb (MyBiosource), anti-CD28 and anti-CD40L mAb (Biorbyt, Cambridge, UK) in incubation buffer containing blocking reagent (Boehringer, Mannheim, Germany) for 45 min. After sections were washed with phosphate-buffered saline (PBS), they were incubated in 1:50 diluted horseradish peroxidase-labelled rabbit anti-mouse IgG (DAKO, Glostrup, Denmark) in incubation buffer for 30 min. After slides were washed in PBS/Tween and PBS, they were mounted [22] .
Culture and activation experiments
For the induction of cytokine production, cultured podocytes were seeded at a final concentration of 5 Â 10 4 cells/well and were treated with AGEs (10 mg/L, 25 mg/L, 50 mg/L and 100 mg/L for 48 h). The cells were then incubated with CD40L (Biorbyt) and recombinant human IL-17 at 50 ng/mL (R&D Systems).
Statistical analysis
Statistical analysis was performed with commercially available SPSS 12.0 software (SPSS Inc., Chicago, IL, USA) with continuous variables. Bonferroni correction was used to determine statistical significance. Differences with P < 0.05 were considered to be statistically significant.
R E S U L T S

CD80 is upregulated in kidney biopsies obtained from patients with DN
To address whether CD80 plays a role in human DN, the expression of CD80 was assessed in kidney biopsies from 49 individuals with DN. All DN specimens were positive for CD80 expression in podocytes (Figure 1a) , while the controls specimens were negative for CD80 expression (Figure 1b) .
Plasma concentrations of sCD28 was detectable in patients with DN
Soluble CD28 (sCD80 soluble ligand), a 44-kDa protein present in the peripheral bloodstream, may be responsible for triggering CD80 expression in podocytes. As shown in Figure 1c , plasma concentrations of sCD28 were found to be inversely correlated with estimated glomerular filtration rate (eGFR) (R 2 ¼ 0.1208, P ¼ 0.005) and serum albumin (R 2 ¼ 0.2049, P < 0.001) in individuals with DN but positively correlated with urine proteinuria (protein to creatinine ratio; R 2 ¼ 0.5836, P < 0.001) and serum uric acid (R 2 ¼ 0.1102, P ¼ 0.008). Plasma sCD28 levels were not correlated to HbA1C (R 2 ¼ 0.0008637, P ¼ 0.822).
CD40 and CD40L is upregulated in kidney biopsies obtained from patients with DN CD40, a 50-kDa transmembrane protein present in podocytes, plays a critical role in activating podocytes to enhance cytokine and chemokine production. The ligand for CD40 is CD154 (CD40L), which is predominantly expressed in activated T cells. CD40-CD40L cross-talk is important in Th17 development. In the healthy human kidneys in this study, only a relatively weak staining of CD40 was detected in a limited number of tubuli ( Figure 1d) þ IL-17 þ T cells infiltrating all parts of the kidney including the glomeruli, the juxta-glomerular apparatus, the interstitium, the tubules and the perivascular area ( Figure 2 ). The exaggerated pathologies observed in the DN kidneys were strongly correlated with increased CD4
þ IL-17 þ T cell infiltration: marked increases in CD4 þ IL-17 þ cell numbers were observed in renal specimens with sclerosis while, in contrast, only minor increases in the number of CD4 þ IL-17 þ cells were noted in renal specimens without sclerosis. IL-17A expression levels were assessed by immunoblotting eight tissue samples collected from renal biopsies of DN patients and 10 control specimens from normal tissue of nephrectomy for angiomyolipoma with massive bleeding or scheduled biopsy from living related kidney donor. IL-17A expression was found to be significantly (P < 0.005) upregulated in DN tissues compared with controls ( Figure 3a) . In parallel, IL-17A expression in the same samples was analysed by ELISA, which revealed that IL-17A was significantly upregulated in DN patient tissues (102.4 612.8 pg/lg total protein) compared with normal control patient tissues (21.4 66.6 pg/lg total protein; P < 0.005).
CD4
þ IL-17 þ cells and IL-17A restrict the decline of renal function Clinically, GFR declines in sclerotic DN patients, which is consistent with an enhanced CD4 þ IL-17 þ T cell response. The marked increase in infiltrating CD4
þ IL-17 þ T cells in renal tissue was inversely correlated with GFR decline (᭝GFR) (Figure 3b) . In vivo tissue levels of IL-17A were also inversely correlated with ᭝GFR (Figure 3c ).
IL-17 and CD40L synergistically enhance the production of IL-6, MCP-1, RANTES and NF-jB in vitro As T cell products, IL-17 and CD40L are both expressed in kidney specimens of DN, and accordingly a possible cooperation between IL-17 and CD-40L was investigated. The activation of podocytes with either IL-17 or CD40L was found to increase IL-6 production over baseline levels (Figure 3d) . Stimulation of podocytes with a combination of IL-17 and CD40L furthermore resulted in synergistic effects on IL-6 production (Figure 3d ). The effects of IL-17 and CD40L on the production of chemokines by podocytes, including MCP-1 and RANTES, were also investigated: MCP-1 production was increased by single stimulation with either IL-17 or CD40L and was more strongly enhanced after combined stimulation (Figure 3d ). RANTES and NF-jB levels were increased by single stimulation with either IL-17 or CD40L, but were more strongly enhanced after combined stimulation.
AGE-induced podocyte activation is characterized by CD40, TGF-b1 and IL-17 production
To elucidate the mechanisms involved in sclerosis of DN, the in vitro pathological responses of podocytes after AGE treatment were assessed and it was found that TGF-b1, CD40 and IL-17 production was significantly enhanced following AGE treatment (Figure 4a ).
Blockade of IL-17 limits TGF-b1 and CD40 production
To investigate a role for IL-17 in TGF-b1 and CD40 production, IL-17 signalling was blocked using the anti-IL-17 monoclonal antibody (mAb). The addition of IL-17 mAb into the podocyte culture medium was found to abrogate TGF-b1 and CD40 expression (Figure 4b ). Electrophoretic mobility shift assays were furthermore performed to investigate NF-jB activation: non-stimulated podocytes exhibited no NF-jB binding activity, which was significantly stimulated by IL-17 and CD40L co-stimulation (Figure 4c ) and inhibited by neutralizing anti-IL-17 antibody. Analysis of the supernatant collected after treatment with anti-IL-17 mAb for 72 h furthermore revealed that TGF-b1 production in podocytes was inhibited by the addition of anti-IL-17 mAb (128 612 and 345 665 pg/mL in treated and untreated samples, respectively; P < 0.01) (Figure 4d ). In addition, anti-IL-17 mAb induced a significant change in CD40 production (58 67 compared with 186 624 ug/mL, with and without the anti-IL-17 mAb, respectively; P < 0.01) (Figure 4e) . Next, the effects of anti-IL-17 mAb exposure on podocyte viability were assessed. MTT assays showed that cell viability increased 
D I S C U S S I O N
In 1994, Paulsen et al. [3] reported T cells in glomeruli of insulin-dependent diabetic subjects. They speculated that the infiltrated T cells contribute to juxtaglomerular body abnormalities in these youth-onset diabetic subjects. Because type 2 DN is not well studied, the actual function of these T cells in diabetic kidneys is unknown. In this study, renal biopsies were performed in patients with type 2 diabetes and heavy proteinuria. In all biopsies, typical Kimmelstiel-Wilson nodules with different degrees of renal fibrosis and mononuclear cell infiltration were identified. In some patients, mononuclear cells were found to be aggregated, resembling germinal centres in the lymph node.
We demonstrate here that CD80 expression is upregulated in podocytes. Histochemical analysis revealed marked CD80 expression in the early phases of DN, whereas CD80 was absent in individuals with DN during diffused glomerulosclerosis in kidney tissue. Plasma sCD28 was also detectable in patients with DN, where plasma sCD28 concentrations were inversely correlated with GFR decline. Immunofluorescence staining showed that both CD40 and CD40L are broadly expressed on infiltrating lymphocytes and CD40L is expressed on podocytes and tubular epithelial cells of DN kidney tissue. We demonstrated the presence of CD4 þ IL-17 þ T cells in all parts of early inflamed DN renal tissue, including in the glomeruli, the juxtaglomerular apparatus, the interstitium, the tubules, and in the perivascular and perisclerotic nodules. CD4
þ IL-17 þ T cells were restricted to the glomerulosclerosis area in late-stage DN. IL-17A tissue expression was shown to be significantly upregulated. Both CD4 þ IL-17 þ T cell tissue infiltration and tissue IL-17A expression were inversely correlated with GFR decline. AGE-induced podocyte production of IL-17, TGF-b and CD40 was down-regulated in response to treatment with anti-IL-17 mAb. Finally, IL-17 and CD40L were shown to synergistically enhance IL-6, MCP-1, RANTES, TGF-b1 and NFjB production from podocytes in vitro.
Upregulation of the CD80-CD28 axis was shown to upregulate the co-stimulatory CD40-CD40L molecule on activated T cells and podocytes. Activated CD40L is known to bind to CD40 on podocytes and is responsible for the persistent activation of podocytes. CD40-CD40L cross-talk furthermore plays a central role in promoting Th17 development: the absence of CD40 impairs Th17 differentiation in vitro and in vivo [7] . The data reported here show that CD40-CD40L upregulation favours the development of the Th17 response.
IL-17 and CD40L are both known to stimulate epithelial cells [8] and are produced or expressed by activated T cells. In this study, therefore, the interaction between CD40L and IL-17 was assessed and it was found that combined stimulation of podocytes with IL-17 and CD40L results in a strong synergistic stimulation of IL-6, MCP-1, RANTES, NF-jB and TGF-b1 The increased MCP-1 production and the synergistically enhanced RANTES production by podocytes in response to IL-17 and CD40L emphasizes the important role of IL-17-producing T cells in DN, particularly considering that the elevated production of these chemokines leads to further attraction of inflammatory cells [23] . The combination of IL-17 and CD40L may therefore play an important role in DN. IL-17-induced CD40 upregulation on podocytes may partially explain the mechanism of synergy between IL-17 and CD40L.
IL-17 levels were assessed in tissue samples collected from renal biopsy specimens and it was found that IL-17 was overexpressed in sclerotic renal tissue compared with non-sclerotic and control kidney tissue. Several studies have demonstrated an important role of IL-17 in tissue remodelling and fibrosis, in a number of different tissues such as lung, intestine and heart [17, 24, 25] . Clinically, the eGFR declined faster in more sclerotic kidneys and the slope of eGFR decline in this study was correlated with infiltrating CD4
þ IL-17 þ T cell numbers in renal tissue. There was no statistically significant correlation between the severity of proteinuria and the number of CD4 þ IL-17 þ T cells; however, this may be due to proteinuria being the result of many types of kidney injury, of which CD4
þ IL-17 þ T cell infiltration is only one.
NF-jB levels were shown to increase following combined IL-17 and CD40L activation of podocytes. IL-17 and IL-17-producing cells are reportedly important in tissue fibrosis [9] [10] [11] [12] [13] [14] and NF-jB blockade by antisense oligonucleotides has been shown to decrease intestinal inflammation and fibrosis in the chronic inflammatory colitis model [25] .
Podocytes were stimulated with AGE in vitro, which revealed that AGE induces IL-17, TGF-b1 and CD40 production in cultured podocytes. Blockade of IL-17 was furthermore shown to inhibit TGF-b1 and CD40 production in cultured podocytes, suggesting that IL-17 contributes to glomerular sclerosis in DN resulting from AGE activation. The findings reported here provide evidence for the expression of both IL-17-secreting CD4
þ IL-17 þ T cells and CD40L in the early stage of DN, where IL-17 and CD40L synergistically increase cytokine and chemokine production as well as NF-jB expression in cultured podocytes and AGE induces CD40, IL-17 and TGFb1 production. Knockdown of IL-17 by IL-17 mAb was furthermore shown to decrease CD40 and TGF-b1 production ( Figure 5 ) and CD4
þ IL-17 þ T cells and IL-17A were shown to restrict the decline of renal function. Podocytes can acquire and process antigens to stimulate specific CD4 þ T cell responses [26] and CD28 and CD40L are known to be expressed on activated CD4 þ T cells [6] . Whether blocking CD80 by CTLA4-Ig (Abatacept) [27] would prevent the synergistic stimulation of renal fibrosis by IL-17 and CD40L remains to be investigated.
From the findings reported in this study, we conclude that podocytes may act as antigen-presenting cells, taking up and processing antigen to initiate a specific T cell response. There is cross-talk between the co-stimulatory molecules CD80-CD28 and CD40L-CD40, and the CD40L-CD40 cross-talk may thus integrate antigenic signals to induce development of IL-17-producing CD4 þ T cells. CD40L is locally expressed in DN kidneys and IL-17 and CD40L synergistically enhance IL-6, MCP-1, RANTES and TGF-b1 production. Blockading of IL-17 was shown to limit TGF-b1 and CD40 production and CD4
þ IL-17 þ T cells restrict declining renal function. These results suggest that IL-17 and CD40L synergistically mediate the inflammatory response and remodelling involved in orchestrating tissue injury and glomerular sclerosis in type 2 DN. The inhibition of IL-17 expression is one of the A limitation of this study is that all specimens of kidney biopsies were from patients with heavy proteinuria, because there is no reason to perform biopsy in the early stage of DN.
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